A multicenter, randomized, parallel-arm, placebo controlled (double blind) and active-controlled (open-label) trial to compare the efficacy and safety of once-weekly lonapegsomatropin with placebo and a daily somatropin product in adults with growth hormone deficiency
Entidad financiadora | Ascendis Pharma Endocrinology Division A/S |
Tipo | Contrato |
Fechas | Desde 01/01/2021 a 31/12/2023 |